20-F: Baird Medical Investment Holdings Limited Navigates Key Regulatory and Financial Milestones in 2024

Baird Medical Investment Holdings Limited reports on its 20-F filing, highlighting regulatory compliance, financial performance, and strategic business activities for the fiscal year ended December 31, 2024.

Summary

• Baird Medical Investment Holdings Limited, a Cayman Islands exempted company, conducts its operations primarily through its PRC subsidiaries.
• The company has obtained several registration certificates for microwave ablation therapeutic apparatus and needles, and a manufacture license valid until May 24, 2026.
• In 2024, there was no cash transfer within the organization.
• The company dismissed Marcum Asia CPAs LLP and appointed Kreit & Chiu CPA LLP as its independent registered public accounting firm, effective from January 24, 2025.
• The company's four largest customers accounted for 25.6%, 14.4%, 11.6% and 10.2% of its total revenue in 2024.
• The company completed filing procedures in connection with the Business Combination under the Overseas Listing Trial Measures on January 2, 2024.
• The company completed the filing procedures in connection with the Business Combination under the Overseas Listing Trial Measures on January 2, 2024, and the result of such CSRC approval was posted on the official website of the CSRC on the same date.
• The company completed the filing procedures in connection with the Business Combination under the Overseas Listing Trial Measures on January 2, 2024.
• The company's revenue increased by 17.7% from US$31.5 million in 2023 to US$37.0 million in 2024.
• The company's gross profit margin was 88.2% in 2024.
• The company's net income increased from US$10.7 million in 2023 to US$12.6 million in 2024.
• The company had cash of approximately US$3.0 million as of December 31, 2024.
• The company has engaged in transactions with related parties, and such transactions present possible conflicts of interest that could have a material and adverse effect on our business, financial conditions and results of operations.

Sentiment

Score: 7

Explanation: The document presents a balanced view with positive financial results but also highlights several risks and challenges. The sentiment is cautiously optimistic.

Positives

• The company has obtained necessary registration certificates and licenses for its medical devices.
• The company's revenue, gross profit margin, and net income increased in 2024.
• The company has a strong market position in the PRC for microwave ablation medical devices.
• The company has a growing network of hospitals purchasing its products.
• The company has a research and development team focused on developing new products.

Negatives

• The company relies on dividends from its PRC subsidiaries, which are subject to PRC regulations.
• The company is subject to uncertainties with respect to the PRC legal system.
• The company's securities may be delisted under the HFCAA if the PCAOB is unable to inspect auditors in mainland China and Hong Kong.
• The price of the company's securities may be volatile.
• The company is a foreign private issuer and is not subject to U.S. proxy rules.
• The company may be treated as a resident enterprise for PRC tax purposes.
• The company may be liable for improper use or appropriation of personal information provided by our customers.
• The company may be subject to fines for our failure to comply with the relevant PRC laws and regulations relating to safety facilities.

Risks

• The company's limited operating history may not be indicative of future growth.
• The company's high gross profit margin may not be sustainable.
• The company may be unable to obtain or renew regulatory filings and registration certificates.
• The company may fail to maintain relationships with existing distributors and customers.
• The company's sales may be affected by the level of medical insurance reimbursement available.
• The Chinese government has significant authority to intervene or influence the company's operations.
• The company's securities may be delisted under the HFCAA.
• The company is subject to uncertainties with respect to the PRC legal system.

Future Outlook

The company expects to continue to evolve and adapt to the changing regulatory framework in China and to expand its sales network.

Industry Context

The company operates in a highly concentrated market in the medical technology industry, characterized by intense competition and rapid technological change.

Comparison to Industry Standards

• The company ranked first among microwave ablation medical device providers in the treatment of thyroid nodules and breast lumps in the PRC in terms of sales revenue and sales volume of microwave ablation needles in 2022.
• The company was the third largest microwave ablation medical device provider in the PRC in terms of sales revenue in 2022.
• The top four microwave ablator manufacturers in 2022 are 1) ECO Medical, 2) Vison Medical, 3) the Company and 4) Canyon Medical.

Related Party Transactions

• In 2023, three of Betters Medicals preference shares holders elected to exercise their right to require Betters Medical, Haimei Wu and certain shareholders of Betters Medical, on a joint and several basis, to repurchase or purchase 100% of their preference shares.
• Haimei Wu, our Chairwoman and Chief Executive Officer, is the legal owner of the premises to which our Tianhe District Usage Certificate was granted, which premises are also co-occupied by the Guangdong branch office of Baide Suzhou.
• Our use of the Taicang Plant is conducted pursuant to a sublease agreement to which certain affiliated entities are parties.
• In addition, we are party to a Subscription Agreement dated June 30, 2021, and certain of our affiliates, as well as the Shareholders Agreement.

Stakeholder Impact

• The company's performance impacts shareholders, employees, customers, suppliers, and creditors.
• The company's ability to pay dividends is dependent on the performance of its PRC subsidiaries.

Next Steps

• The company will continue to dedicate significant resources to protect against unauthorized access to its systems.
• The company will determine the payment of dividends and fund transfer based on its specific business needs in accordance with the applicable laws and regulations.
• The company is planning on promulgating the Guideline for Clinical Evaluation and Registration Review of Thermal Ablation Treatment Systems (Radio Frequency, Microwave, etc.) of the Same Variety (New Clinical Evaluation Guideline) in 2024.

Key Dates

Keywords

medical devices, microwave ablation, financial results, PRC, regulatory, China, Baird Medical, HFCAA